Telix spotlights Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma at EANM congress
TLX•Telix highlighted the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma and other late-stage oncology readouts planned for the Oct. 17-21 European nuclear medicine congress in Vienna.
1. Planned congress readouts
Telix flagged multiple late-stage oncology readouts for the Oct. 17-21 European nuclear medicine congress in Vienna. The presentations will include topline Phase 3 data for Illuccix prostate cancer PET imaging in Chinese men, interim results for TLX597-Tx in metastatic castration-resistant prostate cancer, and updates on Phase 3 programs for TLX101-Tx in recurrent glioblastoma and TLX250-Tx in clear cell renal cell carcinoma.
